ADORA2A and chronic obstructive pulmonary disease: In conclusion, these results demonstrated that BYF exerted its anti-COPD efficacy by restoring the Th17/Treg balance via activating A2aR, which may help to elucidate the underlying immunomodulatory mechanism of BYF and provide evidence for its clinical application in COPD treatment.